Clinical trials: Sitagliptin, completed
Disorder of Glucose Regulation
Sitagliptin + Metformin Compared to Metformin Monotherapy and Placebo in Women With a Recent GDM
Gestational diabetes mellitus (GDM) is defined as "any degree of glucose intolerance with onset or first recognition during pregnancy." GDM is one of the most frequent metabolic disorders occurring during pregnancy.
- Trial name
- NCT01856907
- Testing
- Sitagliptin-Metformin, Metformin
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Woman's
Type 2 Diabetes Mellitus
Ertugliflozin vs. Glimepiride in Type 2 Diabetes Mellitus (T2DM) Participants on Metformin (MK-8835-002)
This study will evaluate the efficacy and safety of the addition of ertugliflozin (MK-8835/PF-04971729) compared with the addition of glimepiride in participants with T2DM who have inadequate glycemic control on metformin.
- Trial name
- NCT01999218
- Testing
- Ertugliflozin 5 mg, Ertugliflozin 10 mg, Glimerpiride
- Volunteers
- 1,326 people
- Sponsor
- Merck Sharp & Dohme LLC
Non-alcoholic Fatty Liver Disease
Efficacy Study of Liraglutide vs.Sitagliptin vs. Glargine on Liver Fat in T2DM Subjects
The aim of this study is to explore the effectiveness of liraglutide combined with metformin in non-alcoholic fatty-liver disease patients with type 2 diabetes mellitus (T2DM) compared to sitagliptin and insulin glargine in…
- Trial name
- LIGHT-ON (NCT02147925)
- Testing
- Liraglutide combined with metformin, Insulin glargine combined with metformin, Sitagliptin combined with metformin
- Where
- China
- Volunteers
- 75 people
- Sponsor
- Sun Yat-sen University
Diabetes Mellitus, Type II
CKD-396 Drug-drug Interaction Study(A) (CKD-396 DDI(A) P1)
The purpose of this study is to evaluate a pharmacokinetic drug interaction between lobeglitazone and sitagliptin in healthy male volunteers.
- Trial name
- NCT02824874
- Testing
- Duvie Tab. 0.5mg, Duvie Tab. 0.5mg + Januvia Tab. 100mg
- Where
- South Korea
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Diabetes Mellitus, Type 2
Efficacy and Long-Term Safety of Vildagliptin as Add-on Therapy to Metformin in Patients With Type 2 Diabetes
This is a 2-3 period parallel group study with an adaptive element in Type 2 diabetes patients receiving vildagliptin as add-on therapy to metformin
- Trial name
- NCT00860288
- Testing
- Vildagliptin, Metformin, Sitagliptin
- Where
- 187 sites in Argentina, Austria and 19 more
- Volunteers
- 1,988 people
- Sponsor
- Novartis Pharmaceuticals
Cushing's Disease, Acromegaly
Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or Acromegaly
The study was designed to investigate the optimal management of hyperglycemia developed during pasireotide treatment in participants with Cushing's disease or Acromegaly, which was not manageable with metformin.
- Trial name
- NCT02060383
- Testing
- Pasireotide s.c., Sitagliptin, Liraglutide
- Where
- 43 sites in United States, Belgium and 10 more
- Volunteers
- 249 people
- Sponsor
- Novartis Pharmaceuticals
Type 2 Diabetes
18-week add-on to Metformin Comparison of Saxagliptin and Sitagliptin in Adult Patients With Type 2 Diabetes (T2D)
Saxagliptin is a new investigational medication being developed for treatment of type 2 diabetes. This study is designed to assess the efficacy and tolerability of saxagliptin in addition to metformin and compare to sitagliptin…
- Trial name
- NCT00666458
- Testing
- saxagliptin, sitagliptin
- Where
- 87 sites in Argentina, Belgium and 7 more
- Volunteers
- 822 people
- Sponsor
- AstraZeneca
Type 2 Diabetes
Therapeutic Efficacy of Triple Combination in Drug-naïve Korean Type 2 Diabetic Patients
Triple combination of metformin, DPP4 inhibitor and Thiazolidinedione would be a good option in the treatment of drug-naïve Korean type 2 diabetic patients.
- Trial name
- NCT02188186
- Testing
- Initial triple combination, Conventional treatment
- Where
- South Korea
- Volunteers
- 200 people
- Sponsor
- Seoul National University Bundang Hospital
Type 2 Diabetes Mellitus
Effects of Gemigliptin Versus Sitagliptin or Glimepiride With Metformin on Glucose Variability(MAGE, Glucose SD) Patients With Type 2 DM(STABLE Study)
To compare efficacy and safety of initial combination therapy of Gemigliptin versus Sitagliptin or Glimepiride with Metformin on Glucose Variability(MAGE, Glucose SD) in Patients With Type 2 Diabetes Mellitus.
- Trial name
- STABLE (NCT01890629)
- Testing
- Gemigliptin + Metformin / Sitagliptin + Metformin / Glimepiride + Metformin
- Where
- South Korea
- Volunteers
- 69 people
- Sponsor
- LG Life Sciences
Diabetes Mellitus, Type 2
Response To Oral Agents in Diabetes (ROAD)- Pilot Study
This proposal is to fund a pilot study to assess feasibility and refine methodology for an intended large Scotland wide study on Response to Oral Agents in Diabetes (ROAD).
- Trial name
- ROAD (NCT00780715)
- Testing
- Gliclazide MR, Sitagliptin, Pioglitazone
- Where
- United Kingdom
- Volunteers
- 29 people
- Sponsor
- University of Dundee
Type 2 Diabetes, Cardiovascular Risk
Canagliflozin and Myocardial Fibrosis
Recently, large clinical intervention studies have demonstrated the cardiovascular protective effects on of sodium-glucose cotransporter 2 inhibitors (SGLT2i) such as empagliflozin, dapagliflozin, and canagliflozin in reduction…
- Trial name
- CANA-DIA-FIB (NCT05367063)
- Testing
- Canagliflozin 100mg or Sitagliptin 100mg
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Shanghai Zhongshan Hospital
Type 2 Diabetes Mellitus
A Study to Assess the Safety and Tolerability of Sitagliptin/Simvastatin Fixed-dose Combination (FDC) in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy (MK-0431D-312)
The purpose of this study is to examine the safety and tolerability of sitagliptin 100 mg/simvastatin 40 mg FDC (MK-0431D) in Vietnamese participants with type 2 diabetes mellitus with inadequate glycemic control on metformin.
- Trial name
- NCT01702298
- Testing
- Sitagliptin 100 mg/simvastatin 40 mg FDC, Metformin
- Volunteers
- 42 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes Mellitus
Remission Evaluation of a Metabolic Intervention in Type 2 Diabetes With Sitagliptin (REMIT-Sita)
The purpose of the study is to determine whether in patients with early type 2 diabetes,a short-term intensive metabolic intervention comprising of sitagliptin, metformin, basal insulin glargine and lifestyle approaches will be…
- Trial name
- NCT02623998
- Testing
- insulin glargine, sitagliptin/metformin, lifestyle therapy
- Where
- 6 sites in Canada
- Volunteers
- 102 people
- Sponsor
- Population Health Research Institute
Metabolic Syndrome, Hypertension
Effect of Sitagliptin and an ACE Inhibitor on Blood Pressure in Metabolic Syndrome
This study will measure the effect of the anti-diabetic agent sitagliptin on blood pressure in individuals with the metabolic syndrome.
- Trial name
- NCT00666848
- Testing
- Enalapril 5mg, Enalapril 10mg, Sitagliptin
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Vanderbilt University
Diabetes Mellitus, Type 2
The Effects of Co-admin of Colesevelam and Sitagliptin on Glucose Metabolism in Subjects With Type 2 Diabetes Mellitus
This study will assess the effects of colesevelam, alone or in combination with sitagliptin, on glucose metabolism in subjects with T2DM inadequately controlled by diet and exercise
- Trial name
- NCT01092663
- Testing
- Colesevelam HCl, Sitagliptin
- Where
- 3 sites in United States
- Volunteers
- 61 people
- Sponsor
- KineMed
Type 2 Diabetes
MAGE of Anagliptin Compared With Sitagliptin With Type 2 Diabetes Mellitus
An exploratory study to evaluate the Effect of Improving Glycemic Variability of Anagliptin Compared with Sitagliptin in Patients with Type 2 Diabetes Mellitus
- Trial name
- ACACIA (NCT04810507)
- Testing
- Anagliptin BID Treatment
- Where
- South Korea
- Volunteers
- 89 people
- Sponsor
- JW Pharmaceutical
Diabetes Mellitus, Type 2, Renal Insufficiency
Safety and Tolerability of Vildagliptin Versus Sitagliptin in Patients With Type 2 Diabetes and Severe Renal Insufficiency (28-week Extension Study)
This clinical trial is designed to provide additional information on the safety and tolerability of vildagliptin (50 mg once daily (qd)) and sitagliptin (25 mg qd) when used in patients with type 2 diabetes mellitus(T2DM) and…
- Trial name
- NCT00770081
- Testing
- vildagliptin, sitagliptin
- Where
- 87 sites in United States
- Volunteers
- 75 people
- Sponsor
- Novartis
Type 2 Diabetes
Study of Sulphonylurea Synergy With DPP4 Inhibitors
The Study of Sulphonylurea Synergy with DPP4 Inhibitors (SSS Study) will establish whether a very low dose of sulphonylurea will have a synergistic role on augmentation of insulin secretion when given in combination with a DPP4…
- Trial name
- SSS (NCT04192292)
- Testing
- Sulfonylurea, DPP4 Inhibitor
- Where
- United Kingdom
- Volunteers
- 30 people
- Sponsor
- University of Dundee
Type 2 Diabetes
Effects of Glutamine on GLP-1 and Insulin Secretion in Man
This study investigated the effect of glutamine, an amino acid, glycemia, glucagon-like peptide-1 (GLP-1) and insulin in participants with type 2 diabetes.
- Trial name
- NCT00673894
- Testing
- Sitagliptin
- Where
- Australia
- Volunteers
- 22 people
- Sponsor
- Garvan Institute of Medical Research
Bioequivalence, Type 2 Diabetes
Comparative Bioavailability Study of Sitagliptin/Metformin 50 mg/1000 mg Tablets in Healthy Male and Female Volunteers
The objective of this study was to determine the bioequivalence of two different formulations of sitagliptin/ metformin after a single oral dose administration under fed conditions.
- Trial name
- NCT05549583
- Testing
- Sitagliptin/metformin hydrochloride (HCl) 50/1000 mg film-coated tablet
- Where
- Canada
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Galenicum Health